ClinVar Miner

Submissions for variant NM_001035.3(RYR2):c.2848G>T (p.Val950Leu) (rs794728731)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000182704 SCV000235084 uncertain significance not provided 2014-04-14 criteria provided, single submitter clinical testing p.Val950Leu (GTG>TTG): c.2848 G>T in exon 25 of the RYR2 gene (NM_001035.2). Approximately 50% of patients with autosomal dominant CPVT have been reported to have a mutation in the RYR2 gene, while mutations in the RYR2 gene associated with ARVC are rare (McNally E et al., 2009; Napolitano C et al., 2012). The V950L variant has not been published as a mutation or reported as a benign polymorphism to our knowledge. The V950L variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. In silico analysis predicts this variant likely does not alter the protein structure/function. Missense mutations in nearby residues have not been reported in association with RYR2-related phenotype, and the V950L variant does not occur in any of the RYR2 mutation hot spots" (Medeiros-Domingo A et al., 2009). However, this substitution occurs at a position that is conserved across species. Furthermore, the V950L variant was not observed in approximately 6,000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant. The variant is found in CARDIOMYOPATHY panel(s)."
Invitae RCV000552549 SCV000637543 uncertain significance Catecholaminergic polymorphic ventricular tachycardia 2019-05-07 criteria provided, single submitter clinical testing This sequence change replaces valine with leucine at codon 950 of the RYR2 protein (p.Val950Leu). The valine residue is highly conserved and there is a small physicochemical difference between valine and leucine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with RYR2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C25"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.